Protara Therapeutics Reports Positive Interim Phase 2 Data for TARA-002 in Bladder Cancer

summarizeSummary

Protara Therapeutics announced updated positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer, showing strong complete response rates and a favorable safety profile in both BCG-Unresponsive and BCG-Naïve patients.

check_boxKey Events

• Positive Phase 2 Interim Data

  TARA-002 demonstrated a 68.2% complete response rate at six months in BCG-Unresponsive NMIBC patients and 66.7% in BCG-Naïve patients.

• Durable Responses Observed

  Among responders, 71.1% (BCG-Unresponsive) and 73.1% (BCG-Naïve) maintained a complete response for six months.

• Favorable Safety Profile

  The trial reported no Grade 3 or greater treatment-related adverse events (TRAEs) and no related serious adverse events.

• Advancing to Registrational Trials

  The company plans to complete enrollment for the BCG-Unresponsive cohort and initiate the ADVANCED-3 registrational trial for BCG-Naïve patients in the second half of 2026.

auto_awesomeAnalysis

The updated interim data from the ADVANCED-2 trial demonstrates TARA-002's potential as a significant treatment option for high-risk non-muscle invasive bladder cancer. The reported complete response rates of 68.2% at six months in BCG-Unresponsive patients and 66.7% at six months in BCG-Naïve patients, coupled with encouraging durability and a clean safety profile (no Grade 3+ TRAEs), are highly encouraging. These results support the company's plans to complete enrollment for the BCG-Unresponsive cohort and initiate a registrational trial for BCG-Naïve patients in the second half of 2026, marking a critical step forward in the drug's development.